Information Provided By: 
Fly News Breaks for February 23, 2016
PTCT
Feb 23, 2016 | 09:33 EDT
After PTC Therapeutics announced that it received a Refuse-to-File letter from the FDA regarding its NDA for Translarna, Oppenheimer analyst Christopher Marai noted that the FDA stated the application was not sufficiently complete and he believes that it is premature to assume that the refusal is data-related. The analyst, who thinks PTC's EU opportunity alone is enough to justify the stock's current valuation, keeps an Outperform rating on the stock.
News For PTCT From the Last 2 Days
There are no results for your query PTCT
